[go: up one dir, main page]

MX2017005578A - Métodos de administración de composiciones de amantadina. - Google Patents

Métodos de administración de composiciones de amantadina.

Info

Publication number
MX2017005578A
MX2017005578A MX2017005578A MX2017005578A MX2017005578A MX 2017005578 A MX2017005578 A MX 2017005578A MX 2017005578 A MX2017005578 A MX 2017005578A MX 2017005578 A MX2017005578 A MX 2017005578A MX 2017005578 A MX2017005578 A MX 2017005578A
Authority
MX
Mexico
Prior art keywords
administration
methods
amantadine
compositions
amantadine compositions
Prior art date
Application number
MX2017005578A
Other languages
English (en)
Other versions
MX376782B (es
Inventor
T Went Gregory
Nguyen Jack
Chernoff David
J Fultz Timothy
Original Assignee
Adamas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals Inc filed Critical Adamas Pharmaceuticals Inc
Publication of MX2017005578A publication Critical patent/MX2017005578A/es
Publication of MX376782B publication Critical patent/MX376782B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los métodos de administración de amantadina para mejorar los trastornos de movimiento, así como las composiciones adecuadas para ello.
MX2017005578A 2014-11-04 2015-11-03 Métodos de administración de composiciones de amantadina. MX376782B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075137P 2014-11-04 2014-11-04
PCT/US2015/058872 WO2016073510A1 (en) 2014-11-04 2015-11-03 Methods of administering amantadine compositions

Publications (2)

Publication Number Publication Date
MX2017005578A true MX2017005578A (es) 2018-01-11
MX376782B MX376782B (es) 2025-03-07

Family

ID=55909712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005578A MX376782B (es) 2014-11-04 2015-11-03 Métodos de administración de composiciones de amantadina.

Country Status (14)

Country Link
US (1) US20160228388A1 (es)
EP (2) EP3909569A1 (es)
JP (1) JP6735020B2 (es)
CN (1) CN107205950B (es)
AU (1) AU2015343199B2 (es)
BR (1) BR112017009289A2 (es)
CA (1) CA2966195C (es)
ES (1) ES2865278T3 (es)
HU (1) HUE055779T2 (es)
MX (1) MX376782B (es)
PL (1) PL3215132T3 (es)
PT (1) PT3215132T (es)
SI (1) SI3215132T1 (es)
WO (1) WO2016073510A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2018320946B2 (en) * 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
TR201720406A2 (tr) 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r i̇skelet kasi gevşeti̇ci̇si̇ ve bi̇r multi̇pl skleroz tedavi̇ edi̇ci̇ ajan i̇çeren kombi̇nasyonlar
WO2019245513A2 (en) 2018-06-21 2019-12-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A combination comprising fingolimod and amantadine
TR201818307A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren bi̇r kompozi̇syon
TR201818859A2 (tr) 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon
TR201819202A2 (tr) 2018-12-12 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bi̇r multi̇pl skleroz ajani ve en az bi̇r kas relaksan ajan i̇çeren bi̇r kombi̇nasyon
TR201820976A2 (tr) 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
WO2014093475A1 (en) * 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
US10154971B2 (en) * 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine

Also Published As

Publication number Publication date
HUE055779T2 (hu) 2021-12-28
EP3215132A4 (en) 2018-07-11
AU2015343199A1 (en) 2017-05-18
JP6735020B2 (ja) 2020-08-05
JP2017533211A (ja) 2017-11-09
WO2016073510A1 (en) 2016-05-12
PL3215132T3 (pl) 2021-10-11
AU2015343199B2 (en) 2021-04-08
EP3215132A1 (en) 2017-09-13
PT3215132T (pt) 2021-05-07
SI3215132T1 (sl) 2021-11-30
BR112017009289A2 (pt) 2017-12-19
EP3215132B1 (en) 2021-01-27
CA2966195C (en) 2024-04-30
US20160228388A1 (en) 2016-08-11
CN107205950A (zh) 2017-09-26
CN107205950B (zh) 2021-06-04
ES2865278T3 (es) 2021-10-15
EP3909569A1 (en) 2021-11-17
MX376782B (es) 2025-03-07
CA2966195A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
CL2018001230A1 (es) Tratamiento de osteoartritis
EA201891211A1 (ru) Ингибиторы cxcr2
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX384024B (es) Peptidos macrociclicos utiles como inmunomoduladores.
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
AR101905A1 (es) Compuestos bicíclicos
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
UY36499A (es) Uso de picolinamidas como fungicidas
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
MX2019012428A (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2017002469A (es) Composiciones de matrices extracelulares.
CL2018000756A1 (es) Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112017001391A2 (pt) componentes para o fusionamento de corpos vertebrais
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
CR20160448A (es) Nuevos derivados de piridina
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ADAMAS PHARMA, LLC